Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMYPAD Prognostic and Natural History Study (PNHS), an open label, prospective, multicentre, cohort study linked to the European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS) in individuals without dementia to evaluate the additional value of quantitative amyloid imaging in determining Alzheimer's Disease (AD) dementia risk AMYPAD [Prognostiche en Natuurlijke Verloop Studie, een open label, prospectieve, multi-center, cohort gerelateerd aan de European Prevention Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS) die in personen zonder dementie evalueert wat de toegevoegde waarde van kwantitatieve amyloïd beeldvorming is in het vaststelen van het risico op het onwikkelen van dementie door de ziekte van Alzheimer]

Trial Profile

AMYPAD Prognostic and Natural History Study (PNHS), an open label, prospective, multicentre, cohort study linked to the European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS) in individuals without dementia to evaluate the additional value of quantitative amyloid imaging in determining Alzheimer's Disease (AD) dementia risk AMYPAD [Prognostiche en Natuurlijke Verloop Studie, een open label, prospectieve, multi-center, cohort gerelateerd aan de European Prevention Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS) die in personen zonder dementie evalueert wat de toegevoegde waarde van kwantitatieve amyloïd beeldvorming is in het vaststelen van het risico op het onwikkelen van dementie door de ziekte van Alzheimer]

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Jan 2019

At a glance

  • Drugs Florbetaben F18 (Primary) ; Flutemetamol-F-18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use
  • Acronyms AMYPAD PNHS
  • Most Recent Events

    • 14 Dec 2018 Planned number of patients changed from 3200 to 2000.
    • 08 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top